Metabolic dysfunction-associated steatotic liver disease (MASLD / MASH / NAFLD)
MASLD, MASH, NAFLD, NASH, fatty liver, steatohepatitis, resmetirom · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Hepatic steatosis (>5% of hepatocytes) with at least one cardiometabolic risk factor and no other cause. Spectrum: simple steatosis -> metabolic dysfunction-associated steatohepatitis (MASH, with inflammation/ballooning) -> fibrosis -> cirrhosis and HCC. Now the commonest chronic liver disease. Management targets metabolic drivers and fibrosis risk stratification.
Red flags
- Features of cirrhosis/portal hypertension (low platelets, splenomegaly, ascites, varices)
- High FIB-4 / high liver stiffness (advanced fibrosis)
- Rapidly rising transaminases or bilirubin (reconsider diagnosis)
- New liver mass / rising AFP (HCC)
- Decompensation: jaundice, ascites, encephalopathy, variceal bleed
Assessment
Differential diagnosis
- Alcohol-associated liver disease (MetALD if both; quantify intake)
- Chronic viral hepatitis (B/C)
- Drug-induced steatosis (methotrexate, tamoxifen, amiodarone, steroids)
- Autoimmune hepatitis
- Haemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency
- Coeliac disease, hypothyroidism, PCOS (associated)
Investigations
- Confirm steatosis (USS/other imaging) and cardiometabolic risk factors (obesity, type 2 diabetes, hypertension, dyslipidaemia)
- Exclude other causes: alcohol history, hepatitis B/C serology, autoimmune (ANA/SMA, immunoglobulins), ferritin/transferrin saturation, caeruloplasmin if young, alpha-1 antitrypsin, TFTs, coeliac
- FIB-4 as first-line non-invasive fibrosis score (age, AST, ALT, platelets); low (<1.3) reassuring, >=1.3 (or >2.0 if >65) needs further assessment
- Transient elastography (FibroScan) / ELF test as second-line fibrosis assessment; liver biopsy in selected uncertain/high-risk cases
- Full metabolic work-up: HbA1c/fasting glucose, lipid profile, BP, BMI/waist; cardiovascular risk assessment
- HCC/varices surveillance if advanced fibrosis/cirrhosis established
Management
- Diagnose MASLD (steatosis + >=1 cardiometabolic criterion) and exclude alternative/co-existing liver disease
- Risk-stratify fibrosis with FIB-4 -> FibroScan/ELF pathway; advanced fibrosis drives prognosis and referral
- Lifestyle is foundation: aim >=7-10% weight loss (improves/resolves MASH and fibrosis); Mediterranean diet, reduce sugar/ultra-processed food, exercise, limit alcohol
- Optimise metabolic comorbidities: treat type 2 diabetes (prefer agents with liver/weight benefit), hypertension, dyslipidaemia - statins are SAFE and indicated for cardiovascular risk
- Consider GLP-1 receptor agonists (e.g. semaglutide) for weight/diabetes with liver benefit; pioglitazone or vitamin E in selected biopsy-proven MASH (non-diabetic) per specialist
- Consider resmetirom for biopsy/imaging-confirmed MASH with F2-F3 fibrosis where available (specialist, with lifestyle)
- Manage the dominant cause of mortality - CARDIOVASCULAR disease - aggressively; bariatric surgery for eligible patients
- Surveillance for HCC and varices if advanced fibrosis/cirrhosis; refer hepatology if advanced fibrosis
Drugs & doses
Weight loss / lifestyle is first-line (target >=7-10% body weight) - no drug replaces this
Resmetirom (THR-beta agonist) PO once daily, weight-based (e.g. 80 mg if <100 kg, 100 mg if >=100 kg) for MASH with F2-F3 fibrosis, with diet/exercise - FDA accelerated approval 2024 [verify local availability/approval]
Semaglutide (GLP-1 RA) SC titrated - for coexisting type 2 diabetes/obesity; approved for MASH (2025) in some regions [verify local]
Pioglitazone 30-45 mg PO once daily in selected biopsy-proven MASH without diabetes (weight gain/fluid caution) [verify local]
Vitamin E 800 IU PO daily in selected non-diabetic biopsy-proven MASH (discuss risks) [verify local]
Statin (e.g. atorvastatin) for cardiovascular risk - safe in MASLD including compensated disease; do not withhold for mildly raised transaminases
Optimise antidiabetic/antihypertensive/lipid therapy per cardiovascular risk
Disposition
Outpatient / primary care with metabolic optimisation. Hepatology referral for advanced fibrosis/cirrhosis, diagnostic uncertainty, or MASH-specific pharmacotherapy. Admit only for decompensation/HCC.
Complications & pitfalls
- Progression to cirrhosis and hepatic decompensation
- Hepatocellular carcinoma (can occur, occasionally without cirrhosis)
- Cardiovascular disease - the LEADING cause of death in MASLD
- Type 2 diabetes, chronic kidney disease, extrahepatic cancers
- Oesophageal varices / portal hypertension if advanced
Exam pearls
- AASLD 2023 / EASL: use FIB-4 first-line to risk-stratify fibrosis, then FibroScan/ELF - fibrosis stage, not steatosis, predicts outcome.
- Resmetirom (Rezdiffra) gained FDA accelerated approval in 2024 as the first drug for MASH with F2-F3 fibrosis, alongside lifestyle - biopsy not mandatory for eligibility. [verify local availability]
- >=7-10% weight loss can resolve MASH and regress fibrosis - lifestyle remains the cornerstone; GLP-1 agonists help weight/diabetes.
- Statins are SAFE and indicated in MASLD - cardiovascular disease, not liver disease, is the commonest cause of death; do not stop statins for mild transaminase rise.
- The nomenclature changed from NAFLD/NASH to MASLD/MASH (2023); MetALD denotes coexisting significant alcohol use - always quantify alcohol intake.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.